Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; Ryanodex injectable suspension for the treatment of malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for the treatment of breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and diclofenac-misoprostol. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid; EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer and mesothelioma; and EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.